Aurobindo Pharma's New Drug Applications Zidovudine Tablets 60mg and Lamivudine & Zidovudine Tablets 30mg / 60mg receives USFDA Approvals

Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Zidovudine Tablets 60mg ((NDA 22-294) and tentative approval for Lamivudine & Zidovudine Tablets 30mg / 60mg ((NDA 22-296) from the US Food & Drug Administration (USFDA).

Both these new drug applications are for pediatric strengths and are developed based on United Nations initiative to develop pediatric formulations. The products are indicated for the treatment of HIV-1 infection in combination with other anti-retrovirals (ARVs).

Aurobindo now has a total of 98 ANDA approvals (70 Final approvals and 28 Tentative approvals) from USFDA, which include 30 products in the ARV segment (8 Final approvals and 22 Tentative approvals)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries.

For further information, please contact:
Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com